Cover Image
市場調查報告書

幽門螺旋桿菌感染疾病:開發平台分析

Helicobacter pylori Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229761
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
幽門螺旋桿菌感染疾病:開發平台分析 Helicobacter pylori Infections - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 75 Pages
簡介

幽門螺旋桿菌是存在於胃中的細菌。胃幽門桿菌的感染疾病一般並沒有症狀。但胃幽門桿菌會引起許多消化器官的異常,例如造成潰瘍和胃癌等的可能性。幽門螺旋桿菌感染疾病,一般是透過被糞污染的食物跟水傳染。由於會放出造成胃及十二指腸細胞直接或間接傷害的酵素或毒素,所以會改變胃及十二指腸的狀態,其結果可能導致胃潰瘍和十二指腸潰瘍。最常見的症狀有疼痛和不適感(通常是上腹部)、飽脹感(少量進食後)、食慾不振、噁心和嘔吐、黑色、焦油色糞便、出血性潰瘍等,也可能引起血球過低或疲勞。

本報告提供幽門螺旋桿菌感染疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

幽門螺旋桿菌感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Daewoong Pharmaceutical Co., Ltd.
  • EpiVax, Inc.
  • ImevaX GmbH
  • ImmunoBiology Limited
  • RedHill Biopharma Ltd.
  • Sequella, Inc.
  • Shanghai Zerun Biotechnology Co., Ltd.
  • Sigmoid Pharma Limited

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (rifabutin + amoxicillin sodium + omeprazole sodium)
  • DWJ-1325
  • FROST-900
  • Helicobacter pylori Hel-305 (multivalent) vaccine
  • helicobacter pylori vaccine
  • helicobacter pylori vaccine
  • helicobacter pylori vaccine
  • helicobacter pylori vaccine
  • HPi-1
  • IMX-101
  • Small Molecules for Helicobacter Pylori Infections
  • Small Molecules to Inhibit DNA Synthesis for Infectious Diseases
  • SQ-109

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8283IDB

Summary

Global Markets Direct's, 'Helicobacter pylori Infections - Pipeline Review, H2 2016', provides an overview of the Helicobacter pylori Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Helicobacter pylori Infections
  • The report reviews pipeline therapeutics for Helicobacter pylori Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Helicobacter pylori Infections therapeutics and enlists all their major and minor projects
  • The report assesses Helicobacter pylori Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Helicobacter pylori Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Helicobacter pylori Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Helicobacter pylori Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Helicobacter pylori Infections Overview
  • Therapeutics Development
    • Pipeline Products for Helicobacter pylori Infections - Overview
    • Pipeline Products for Helicobacter pylori Infections - Comparative Analysis
  • Helicobacter pylori Infections - Therapeutics under Development by Companies
  • Helicobacter pylori Infections - Therapeutics under Investigation by Universities/Institutes
  • Helicobacter pylori Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Helicobacter pylori Infections - Products under Development by Companies
  • Helicobacter pylori Infections - Products under Investigation by Universities/Institutes
  • Helicobacter pylori Infections - Companies Involved in Therapeutics Development
    • Daewoong Pharmaceutical Co., Ltd.
    • Debiopharm International SA
    • EpiVax, Inc.
    • Frost Biologic, Inc.
    • ImevaX GmbH
    • ImmunoBiology Limited
    • Recce Pty Ltd
    • RedHill Biopharma Ltd.
    • Sequella, Inc.
    • Sigmoid Pharma Limited
  • Helicobacter pylori Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amoxicillin sodium + omeprazole sodium + rifabutin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Debio-1453 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-1325 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FROST-900 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPi-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RECCE-327 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Helicobacter Pylori Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SQ-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Helicobacter pylori Infections - Dormant Projects
  • Helicobacter pylori Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2016: RedHill Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection
      • Mar 08, 2016: RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection
      • Mar 01, 2016: RedHill Biopharma Provides Update on RHB-105
      • Sep 08, 2015: RedHill Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study's Positive Results
      • Aug 26, 2015: Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection
      • Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection
      • Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection
      • Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study
      • Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results
      • May 18, 2015: RedHill Biopharma's Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market
      • May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study
      • Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection
      • Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment
      • Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105
      • Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Helicobacter pylori Infections, H2 2016
  • Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Helicobacter pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Helicobacter pylori Infections - Pipeline by Debiopharm International SA , H2 2016
  • Helicobacter pylori Infections - Pipeline by EpiVax, Inc., H2 2016
  • Helicobacter pylori Infections - Pipeline by Frost Biologic, Inc., H2 2016
  • Helicobacter pylori Infections - Pipeline by ImevaX GmbH, H2 2016
  • Helicobacter pylori Infections - Pipeline by ImmunoBiology Limited, H2 2016
  • Helicobacter pylori Infections - Pipeline by Recce Pty Ltd, H2 2016
  • Helicobacter pylori Infections - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Helicobacter pylori Infections - Pipeline by Sequella, Inc., H2 2016
  • Helicobacter pylori Infections - Pipeline by Sigmoid Pharma Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Helicobacter pylori Infections - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Helicobacter pylori Infections, H2 2016
  • Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top